Leigh Brody
Investment Manager
Joined 2021
Overview
Leigh specialises in transformative technologies and therapeutics opportunities in life sciences. She joined the team in 2021 after pursuing her own startup career. The investment manager initially led a spin-out based around her own novel technology, before helping to build several early-stage life science companies. These include Desktop Genetics and Quell Therapeutics.
The investor deploys her experience as an academic and founder to select innovators with potential. and provides the support that spin-outs require.
Leigh gained her PhD from Imperial College London, and also holds a BSc in Biochemistry from Simmons University. She has also been awarded of 50 Movers & Shakers in BioBusiness, 35 under 35: Tech Entrepreneurs.
Personal
Whenever Boston-born Leigh isn’t running after her two children, she is most likely to be found racing around a running track – ideally with a finish line near somewhere offering good food and wine. She dedicates her free moments to pursuing her side hustles, which include formulating a skincare line and writing a children’s book. She also finds time to mentor STEM programs for young people.
Leigh currently supports Bloomsbury GTX and CS Genetics.
Featured content
Universities should not be greedy with technology spin-offs | FT
Dave Grimm, Partner at AlbionVC, chats to John Gapper, Financial Times, on the opportunities that commercialising research presents, on the back of our very successful partnership with UCL.
UK universities take record low spinout stakes: ‘But that’s only half the battle’
David Grimm, Partner AlbionVC discusses university spinout terms and timelines with Sifted
Today, 90% of Russell Group universities have affiliated funds as reported by Sifted
Why We’re Bullish on London University Spinouts